본문 바로가기
KERD
논문KCI 등재

Heart Failure as a Risk Factor for Stroke

Woohyeun Kim|Eung Ju Kim
대한뇌졸중학회 (The Korean Stroke Society)|2018.01|대한뇌졸중영문학회지 (Journal of stroke)|제20권 제1호|pp. 33-45|DOI https://doi.org/10.5853/jos.2017.02810

2

조회

0

다운로드

6

인용

0

참고문헌

키워드

StrokeHeart failureCHA2DS2-VASc score
주제분류신경과학

초록

Heart failure (HF) is one of the major causes of death worldwide. Despite the high incidence of stroke in patients with HF, there has been a controversy as to whether HF itself is a risk factor for stroke. Recently, there is a great deal of evidence that HF itself increases the risk of stroke. In previous studies, the benefit of warfarin for stroke prevention in patients with HF was offset by the risk of bleeding. In the era of non-vitamin K antagonist oral anticoagulants with low bleeding profiles, we can expect a more effective stroke prevention in patients with HF by selective anticoagulation. The purpose of this review is to describe the relationship between stroke and HF, which could be an unconventional risk factor and a potential intervention target for stroke prevention.

Abstract

Heart failure (HF) is one of the major causes of death worldwide. Despite the high incidence of stroke in patients with HF, there has been a controversy as to whether HF itself is a risk factor for stroke. Recently, there is a great deal of evidence that HF itself increases the risk of stroke. In previous studies, the benefit of warfarin for stroke prevention in patients with HF was offset by the risk of bleeding. In the era of non-vitamin K antagonist oral anticoagulants with low bleeding profiles, we can expect a more effective stroke prevention in patients with HF by selective anticoagulation. The purpose of this review is to describe the relationship between stroke and HF, which could be an unconventional risk factor and a potential intervention target for stroke prevention.

참고문헌 (121)

  1. Feigin VL, "Global burden of stroke", Circ Res, 120, pp.439~448 (2017)[DOI]
  2. Feigin VL, "Update on the global burden of ischemic and hemorrhagic stroke in 1990-2013: the GBD 2013 study", Neuroepidemiology, 45, pp.161~176 (2015)[DOI]
  3. GBD 2015 Disease, "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015", Lancet, 388, pp.1545~1602 (2016)[DOI]
  4. Pullicino PM, "Blood pressure and stroke in heart failure in the REasons for Geographic And Racial Differences in Stroke (REGARDS) study", Stroke, 40, pp.3706~3710 (2009)[DOI]
  5. Kannel WB, "Manifestations of coronary disease predisposing to stroke. The Framingham study", JAMA, 250, pp.2942~2946 (1983)[DOI]
  6. Witt BJ, "Ischemic stroke after heart failure: a community-based study", Am Heart J, 152, pp.102~109 (2006)[DOI]
  7. Ziaeian B, "Epidemiology and aetiology of heart failure", Nat Rev Cardiol, 13, pp.368~378 (2016)[DOI]
  8. Ponikowski P, "2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC", Eur Heart J, 37, pp.2129~2200 (2016)[DOI]
  9. Writing Group Members, "Heart disease and stroke statistics: 2010 update. A report from the American Heart Association", Circulation, 121, pp.e46~e215 (2010)[DOI]
  10. Writing Group Members, "Heart disease and stroke statistics: 2016 update. A report from the American Heart Association", Circulation, 133, pp.e38~e360 (2016)[DOI]
  11. Ponikowski P, "Heart failure: preventing disease and death worldwide", ESC Heart Fail, 1, pp.4~25 (2014)[DOI]
  12. Maggioni AP, "EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot)", Eur J Heart Fail, 15, pp.808~817 (2013)[DOI]
  13. Mamas MA, "Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland", Eur J Heart Fail, 19, pp.1095~1104 (2017)[DOI]
  14. Divani AA, "Nationwide frequency and association of heart failure on stroke outcomes in the United States", J Card Fail, 15, pp.11~16 (2009)[DOI]
  15. Ois A, "Heart failure in acute ischemic stroke", J Neurol, 255, pp.385~389 (2008)[DOI]
  16. Hays AG, "Left ventricular systolic dysfunction and the risk of ischemic stroke in a multiethnic population", Stroke, 37, pp.1715~1719 (2006)[DOI]
  17. Appelros P, "Poor outcome after firstever stroke: predictors for death, dependency, and recurrent stroke within the first year", Stroke, 34, pp.122~126 (2003)[DOI]
  18. Pullicino P, "Stroke in heart failure: atrial fibrillation revisited?", J Stroke Cerebrovasc Dis, 19, pp.1~2 (2010)[DOI]
  19. Haeusler KG, "Chronic heart failure and ischemic stroke", Stroke, 42, pp.2977~2982 (2011)[DOI]
  20. Adelborg K, "Risk of stroke in patients with heart failure: a population-based 30-year cohort study", Stroke, 48, pp.1161~1168 (2017)[DOI]
  21. Sacco RL, "American Heart Association Prevention Conference. IV. Prevention and rehabilitation of stroke. Risk factors", Stroke, 28, pp.1507~1517 (1997)[DOI]
  22. Lip GY, "Stroke and mortality in patients with incident heart failure: the Diet, Cancer and Health (DCH) cohort study", BMJ Open, 2, pp.e000975~ (2012)[DOI]
  23. Alberts VP, "Heart failure and the risk of stroke: the Rotterdam Study", Eur J Epidemiol, 25, pp.807~812 (2010)[DOI]
  24. Freudenberger RS, "Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)", Circulation, 115, pp.2637~2641 (2007)[DOI]
  25. Szummer KE, "Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry", Eur Heart J, 26, pp.2114~2119 (2005)[DOI]
  26. Loh E, "Ventricular dysfunction and the risk of stroke after myocardial infarction", N Engl J Med, 336, pp.251~257 (1997)[DOI]
  27. Dries DL, "Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials", J Am Coll Cardiol, 29, pp.1074~1080 (1997)[DOI]
  28. Anter E, "Atrial fibrillation and heart failure: treatment considerations for a dual epidemic", Circulation, 119, pp.2516~2525 (2009)[DOI]
  29. Hohendanner F, "Pathophysiological and therapeutic implications in patients with atrial fibrillation and heart failure", Heart Fail Rev, 23, pp.27~36 (2018)[DOI]
  30. Abraham JM, "Atrial fibrillation in heart failure: stroke risk stratification and anticoagulation", Heart Fail Rev, 19, pp.305~313 (2014)[DOI]
  31. Santhanakrishnan R, "Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction", Circulation, 133, pp.484~492 (2016)
  32. Kang SH, "Risk of stroke in congestive heart failure with and without atrial fibrillation", Int J Cardiol, 248, pp.182~187 (2017)[DOI]
  33. Kotecha D, "Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: a systematic review and meta-analysis of death and adverse outcomes", Int J Cardiol, 203, pp.660~666 (2016)[DOI]
  34. Mogensen UM, "Type of atrial fibrillation and outcomes in patients with heart failure and reduced ejection fraction", J Am Coll Cardiol, 70, pp.2490~2500 (2017)[DOI]
  35. Lip GY, "Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis", Thromb Haemost, 108, pp.1009~1022 (2012)[DOI]
  36. Abdul-Rahim AH, "Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials", Eur Heart J, 38, pp.742~750 (2017)
  37. Abdul-Rahim AH, "Risk of stroke in chronic heart failure patients without atrial fibrillation: analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) trials", Circulation, 131, pp.1486~1494 (2015)[DOI]
  38. Freudenberger RS, "Risk of thromboembolism in heart failure", Circulation, 115, pp.2637~2641 (2007)[DOI]
  39. Su MY, "CMR-verified diffuse myocardial fibrosis is associated with diastolic dysfunction in HFpEF", JACC Cardiovasc Imaging, 7, pp.991~997 (2014)[DOI]
  40. Zile MR, "Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction", Circulation, 124, pp.2491~2501 (2011)[DOI]
  41. Borlaug BA, "Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment", Eur Heart J, 32, pp.670~679 (2011)[DOI]
  42. Ferro JM, "Cardioembolic stroke: an update", Lancet Neurol, 2, pp.177~188 (2003)[DOI]
  43. Cusick DA, "Left ventricular apical thrombus and myocardial viability: a dobutamine stress echocardiographic study", Echocardiography, 17(6), pp.547~554 (2000)[DOI]
  44. Merlini PA, "Persistent activation of coagulation mechanism in unstable angina and myocardial infarction", Circulation, 90, pp.61~68 (1994)[DOI]
  45. Bhatnagar SK, "Left ventricular thrombosis, wall motion abnormalities, and blood viscosity changes after first transmural anterior myocardial infarction", Chest, 88, pp.40~44 (1985)[DOI]
  46. Cicala S, "Prevalence and prognostic significance of wall-motion abnormalities in adults without clinically recognized cardiovascular disease: the Strong Heart Study", Circulation, 116, pp.143~150 (2007)[DOI]
  47. Choi JY, "Left ventricular wall motion abnormalities are associated with stroke recurrence", Neurology, 88, pp.586~594 (2017)[DOI]
  48. Shepherd J, "Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group", N Engl J Med, 333, pp.1301~1307 (1995)[DOI]
  49. Keun-Sik Hong, "Statins in Acute Ischemic Stroke: A Systematic Review", 대한뇌졸중영문학회지, 17(3), pp.282~301 (2015), 대한뇌졸중학회
  50. Choi JY, "Statins improve survival in patients with cardioembolic stroke", Stroke, 45, pp.1849~1852 (2014)[DOI]
  51. Hassell ME, "Silent cerebral infarcts associated with cardiac disease and procedures", Nat Rev Cardiol, 10, pp.696~706 (2013)[DOI]
  52. Kozdag G, "Silent cerebral infarction in chronic heart failure: ischemic and nonischemic dilated cardiomyopathy", Vasc Health Risk Manag, 4, pp.463~469 (2008)[DOI]
  53. Vogels RL, "Brain magnetic resonance imaging abnormalities in patients with heart failure", Eur J Heart Fail, 9, pp.1003~1009 (2007)[DOI]
  54. Siachos T, "Silent strokes in patients with heart failure", J Card Fail, 11, pp.485~489 (2005)[DOI]
  55. Schmidt R, "Brain magnetic resonance imaging and neuropsychologic evaluation of patients with idiopathic dilated cardiomyopathy", Stroke, 22, pp.195~199 (1991)[DOI]
  56. Kozdag G, "Silent cerebral infarction in patients with dilated cardiomyopathy: echocardiographic correlates", Int J Cardiol, 107, pp.376~381 (2006)[DOI]
  57. Havakuk O, "Heart failure-induced brain injury", J Am Coll Cardiol, 69, pp.1609~1616 (2017)
  58. Dardiotis E, "Cognitive impairment in heart failure", Cardiol Res Pract, 2012, pp.595821~ (2012)
  59. Almeida OP, "Cognitive and brain changes associated with ischaemic heart disease and heart failure", Eur Heart J, 33, pp.1769~1776 (2012)[DOI]
  60. Vogels RL, "Cognitive impairment in heart failure: a systematic review of the literature", Eur J Heart Fail, 9, pp.440~449 (2007)[DOI]
  61. Sauve MJ, "Cognitive impairments in chronic heart failure: a case controlled study", J Card Fail, 15, pp.1~10 (2009)[DOI]
  62. Huijts M, "Cognitive impairment in heart failure: results from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF) randomized trial", Eur J Heart Fail, 15, pp.699~707 (2013)[DOI]
  63. Athilingam P, "Cognitive profile in persons with systolic and diastolic heart failure", Congest Heart Fail, 19, pp.44~50 (2013)[DOI]
  64. Zuccala G, "Use of angiotensin-converting enzyme inhibitors and variations in cognitive performance among patients with heart failure", Eur Heart J, 26, pp.226~233 (2005)[DOI]
  65. Mohr JP, "Etiology of stroke", Stroke, 28, pp.1501~1506 (1997)[DOI]
  66. Haeusler KG, "Relevance of heart failure in prevention, treatment and prognosis of ischemic stroke", Neurol Int Open, 1, pp.E61~E64 (2017)[DOI]
  67. Lip GY, "Does heart failure confer a hypercoagulable state? Virchow's triad revisited", J Am Coll Cardiol, 33, pp.1424~1426 (1999)[DOI]
  68. Di Tullio MR, "Left ventricular ejection fraction and risk of stroke and cardiac events in heart failure: data from the warfarin versus aspirin in reduced ejection fraction trial", Stroke, 47, pp.2031~2037 (2016)[DOI]
  69. Falk RH, "Ventricular thrombi and thromboembolism in dilated cardiomyopathy: a prospective followup study", Am Heart J, 123, pp.136~142 (1992)[DOI]
  70. Meltzer RS, "Intracardiac thrombi and systemic embolization", Ann Intern Med, 104, pp.689~698 (1986)[DOI]
  71. Pullicino PM, "Stroke in patients with heart failure and reduced left ventricular ejection fraction", Neurology, 54, pp.288~294 (2000)[DOI]
  72. Wolf PA, "Atrial fibrillation as an independent risk factor for stroke: the Framingham Study", Stroke, 22, pp.983~988 (1991)[DOI]
  73. Jug B, "Procoagulant state in heart failure with preserved left ventricular ejection fraction", Int Heart J, 50, pp.591~600 (2009)[DOI]
  74. de Peuter OR, "Systolic heart failure: a prothrombotic state", Semin Thromb Hemost, 35, pp.497~504 (2009)[DOI]
  75. Chong AY, "Viewpoint: the prothrombotic state in heart failure: a maladaptive inflammatory response?", Eur J Heart Fail, 9, pp.124~128 (2007)[DOI]
  76. Lee KW, "Impaired tissue Doppler diastolic function in patients with coronary artery disease: relationship to endothelial damage", dysfunction and platelet activation, 2005, pp.150, 756~766
  77. Chin BS, "Interleukin-6, tissue factor and von Willebrand factor in acute decompensated heart failure: relationship to treatment and prognosis", Blood Coagul Fibrinolysis, 14, pp.515~521 (2003)[DOI]
  78. Jafri SM, "Effects of warfarin on markers of hypercoagulability in patients with heart failure", Am Heart J, 134, pp.27~36 (1997)[DOI]
  79. Jafri SM, "Hypercoagulability in heart failure", Semin Thromb Hemost, 23, pp.543~545 (1997)[DOI]
  80. Lip GY, "Is diastolic dysfunction associated with thrombogenesis? A study of circulating markers of a prothrombotic state in patients with coronary artery disease", Int J Cardiol, 50, pp.31~42 (1995)[DOI]
  81. Lip GY, "Effects of warfarin therapy on plasma fibrinogen, von Willebrand factor, and fibrin D-dimer in left ventricular dysfunction secondary to coronary artery disease with and without aneurysms", Am J Cardiol, 76, pp.453~458 (1995)[DOI]
  82. Sbarouni E, "Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure", Am Heart J, 127, pp.607~612 (1994)[DOI]
  83. Jafri SM, "Platelet function, thrombin and fibrinolytic activity in patients with heart failure", Eur Heart J, 14, pp.205~212 (1993)[DOI]
  84. Keber I, "Tissue plasminogen activator release in chronic venous hypertension due to heart failure", Thromb Haemost, 68, pp.321~324 (1992)
  85. Gibbs CR, "Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy", Circulation, 103, pp.1746~1751 (2001)[DOI]
  86. Niebauer J, "Endotoxin and immune activation in chronic heart failure: a prospective cohort study", Lancet, 353, pp.1838~1842 (1999)[DOI]
  87. Kubo SH, "Endothelium-dependent vasodilation is attenuated in patients with heart failure", Circulation, 84, pp.1589~1596 (1991)[DOI]
  88. Georgiadis D, "Cerebrovascular reactivity is impaired in patients with cardiac failure", Eur Heart J, 21, pp.407~413 (2000)[DOI]
  89. Rajagopalan B, "Changes in cerebral blood flow in patients with severe congestive cardiac failure before and after captopril treatment", Am J Med, 76(5B), pp.86~90 (1984)[DOI]
  90. Lorenzi-Filho G, "Relationship of carbon dioxide tension in arterial blood to pulmonary wedge pressure in heart failure", Eur Respir J, 19, pp.37~40 (2002)[DOI]
  91. Derdeyn CP, "Variability of cerebral blood volume and oxygen extraction: stages of cerebral haemodynamic impairment revisited", Brain, 125, pp.595~607 (2002)[DOI]
  92. Weber T, "Pulsatile hemodynamics in patients with exertional dyspnea: potentially of value in the diagnostic evaluation of suspected heart failure with preserved ejection fraction", J Am Coll Cardiol, 61, pp.1874~1883 (2013)[DOI]
  93. Vemmos K, "Stroke aetiology and predictors of outcome in patients with heart failure and acute stroke: a 10-year follow-up study", Eur J Heart Fail, 14, pp.211~218 (2012)[DOI]
  94. He J, "Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study", Arch Intern Med, 161, pp.996~1002 (2001)[DOI]
  95. Massie BM, "Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management", Am Heart J, 133, pp.703~712 (1997)[DOI]
  96. Kannel WB, "Changing epidemiological features of cardiac failure", Br Heart J, 72(2 Suppl), pp.S3~S9 (1994)
  97. Lee SE, "A multicentre cohort study of acute heart failure syndromes in Korea: rationale, design, and interim observations of the Korean Acute Heart Failure (KorAHF) registry", Eur J Heart Fail, 16, pp.700~708 (2014)[DOI]
  98. Kirchhof P, "2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS", Eur Heart J, 37, pp.2893~2962 (2016)[DOI]
  99. January CT, "2014 AHA", ACC, American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society, pp.J Am Coll Cardiol, 2014[DOI]
  100. Cleland JG, "The Warfarin", Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure, 2004, pp.148, 157~164
  101. Cokkinos DV, "Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study", Eur J Heart Fail, 8, pp.428~432 (2006)[DOI]
  102. Massie BM, "Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial", Circulation, 119, pp.1616~1624 (2009)[DOI]
  103. Homma S, "Warfarin and aspirin in patients with heart failure and sinus rhythm", N Engl J Med, 366, pp.1859~1869 (2012)[DOI]
  104. Hopper I, "Updated meta-analysis on antithrombotic therapy in patients with heart failure and sinus rhythm", Eur J Heart Fail, 15, pp.69~78 (2013)[DOI]
  105. Kondo T, "The CHADS2 score predicts ischemic stroke in chronic heart failure patients without atrial fibrillation: comparison to other stroke risk scores", Heart Vessels, 32, pp.193~200 (2017)[DOI]
  106. Melgaard L, "Assessment of the CHA2DS2-VASc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation", JAMA, 314, pp.1030~1038 (2015)[DOI]
  107. Melgaard L, "Female sex is associated with a lower risk of stroke in patients with heart failure", Am Heart J, 169, pp.396~403 (2015)[DOI]
  108. Syeda Atiqa Batul, "Atrial Fibrillation in Heart Failure: a Therapeutic Challenge of Our Times", Korean Circulation Journal, 47(5), pp.644~662 (2017), 대한심장학회[DOI]
  109. Giugliano RP, "Edoxaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 369, pp.2093~2104 (2013)[DOI]
  110. Patel MR, "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation", N Engl J Med, 365, pp.883~891 (2011)[DOI]
  111. Granger CB, "Apixaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 365, pp.981~992 (2011)[DOI]
  112. Connolly SJ, "Dabigatran versus warfarin in patients with atrial fibrillation", N Engl J Med, 361, pp.1139~1151 (2009)[DOI]
  113. Ferreira J, "Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial", Eur J Heart Fail, 15, pp.1053~1061 (2013)[DOI]
  114. van Diepen S, "Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF", Circ Heart Fail, 6, pp.740~747 (2013)[DOI]
  115. Magnani G, "Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48", Eur J Heart Fail, 18, pp.1153~1161 (2016)[DOI]
  116. McMurray JJ, "Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial", Circ Heart Fail, 6, pp.451~460 (2013)[DOI]
  117. Isnard R, "Non-vitamin K antagonist oral anticoagulants and heart failure", Arch Cardiovasc Dis, 109, pp.641~650 (2016)[DOI]
  118. Xiong Q, "Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials", Eur J Heart Fail, 17, pp.1192~1200 (2015)[DOI]
  119. Yeh CH, "Overview of the new oral anticoagulants: opportunities and challenges", Arterioscler Thromb Vasc Biol, 35, pp.1056~1065 (2015)[DOI]
  120. Mega JL, "Rivaroxaban in patients with a recent acute coronary syndrome", N Engl J Med, 366, pp.9~19 (2012)[DOI]
  121. Zannad F, "Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial", Eur J Heart Fail, 17, pp.735~742 (2015)[DOI]

관련 논문AI추천

The Mechanism of and Preventive Therapy for Stroke in Patients with Atrial Fibrillation노승영, Young-Hoon Kim대한뇌졸중학회 · 대한뇌졸중영문학회지2016 · 제18권 제2호Association between Heart Failure and Clinical Prognosis in Patients with Acute Ischemic Stroke: A Retrospective Cohort StudyFabián Cortés Muñoz, Fernán del Cristo Mendoza Beltrán, Javier Francisco Torres Zafra, Jenny Carolina Sánchez Casas, Jose Luis Lozano Villanueva, Luis Alfonso Barragán Pedraza대한신경과학회 · Journal of Clinical Neurology2021 · 제17권 제2호Occurrence of Ischemic Stroke in Patients With Atrial Fibrillation Receiving Non-Vitamin K Oral Anticoagulants: Causes and Prevention StrategiesDong Seop Jeong, Kyoung-Min Park, Oh Young Bang대한뇌졸중학회 · 대한뇌졸중영문학회지2023 · 제25권 제2호Practical Issues to Prevent Stroke Associated with Non-valvular Atrial Fibrillation김치경, 윤병우, 정승욱대한뇌졸중학회 · 대한뇌졸중영문학회지2013 · 제15권 제3호Factors Associated with Ischemic Stroke on Therapeutic Anticoagulation in Patients with Nonvalvular Atrial Fibrillation김규식, 김서현, 김영대, 김은혜, 남정모, 남효석, 박희남, 송동범, 안성환, 오승헌, 이경열, 이기욱, 이기정, 이종윤, 이혜선, 정요한, 조한진, 차명진, 최혜연, 한상돈, 한상원, 허지회연세대학교의과대학 · Yonsei Medical Journal2015 · 제56권 제2호Updates on Prevention of Cardioembolic Strokes김동억, Liping Liu, M. Edip Gurol, Mehmet Akif Topcuoglu대한뇌졸중학회 · 대한뇌졸중영문학회지2018 · 제20권 제2호

이 간행물의 다른 논문 (14건)

Unconventional, Yet Important, Risk Factors for StrokeJong S. Kimpp. 1-1Air Pollution and StrokeKuan Ken Lee, Mark R. Miller, Anoop S. V. Shahpp. 2-11Sleep Disturbances as a Risk Factor for StrokeHyunwoo Nam, Chang-Ho Yun, Robert J. Thomas, Dae Lim Koopp. 12-32Development of New Endovascular Devices for Aneurysm TreatmentJae Jon Sheen, Deok Hee Lee, Hai Bin Shi, Joong-Goo Kim, Dae Chul Suh, Zhen Yu Jia, Shigeru Miyachi, Sun Moon Hwang, Yun Sun Songpp. 46-56Treatments to Promote Neural Repair after StrokeSteven C. Cramerpp. 57-70
원문 보기